News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|August 7, 2015

The Diagnosis of Prostate Cancer

Episodes in this series

EP. 1 The Diagnosis of Prostate Cancer

EP. 1 The Diagnosis of Prostate Cancer

EP. 2 Prostate Blood Test: Understanding the Tests

EP. 2 Prostate Blood Test: Understanding the Tests

EP. 3 A Caregiver's Account

EP. 3 A Caregiver's Account

EP. 4 Importance of the Empowered Patient

EP. 4 Importance of the Empowered Patient

EP. 5 Dr. Petrylak: Advice From an Oncologist

EP. 5 Dr. Petrylak: Advice From an Oncologist

EP. 6 Dr. Petrylak: The Future of Prostate Cancer

EP. 6 Dr. Petrylak: The Future of Prostate Cancer

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Dexamethasone May Ease Severe Neurotoxicity With Yescarta in LBCL

December 9th 2025

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

New Data Support Pelabresib Combination in Untreated Myelofibrosis

December 9th 2025

$Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.$

Tecvayli Treatment Combo Improves Outcomes in Relapsed/Refractory Myeloma

ByJason Broderick

December 9th 2025

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL: © stock.adobe.com.

Jaypirca Significantly Improves PFS Outcomes in Untreated CLL/SLL

BySabrina Serani

December 9th 2025

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Breaking Down the Prostate Cancer Treatment Renaissance

December 9th 2025

Trending on CURE

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

Epkinly Plus Chemo Elicits Durable Responses in DLBCL

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

Insights Into What’s New in Blood Cancer Care

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

© 2025 MJH Life Sciences^®

All rights reserved.